SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 24, 2019--
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey.
“I am so proud of our more than 300 employees and their contributions in creating and sustaining a positive culture at Veracyte, especially as we’ve grown and commercialized five products since our founding in 2008,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Being one of very few companies to receive this prestigious award six years in a row is an honor and reflects our employees’ dedication and commitment to improving the lives of patients and to each other.”
The Top Workplaces award winners are determined by results of a survey administered by Energage, LLC, a leading provider of technology-based engagement tools. The survey measures several key aspects of workplace culture, including organizational alignment, effective execution and meaningful connection with employees.
“Top Workplaces is more than just recognition,” said Doug Claffey, chief executive officer of Energage. “Our research shows organizations that earn the award attract better talent, experience lower turnover, and are better equipped to deliver bottom-line results. Their leaders prioritize and carefully craft a healthy workplace culture that supports employee engagement.”
The Bay Area News Group published the complete list of 2019 Top Workplaces on Sunday, June 23. The list of winners is available at the Bay Area News Group website.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized five genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005200/en/
Source: Veracyte, Inc.
Investor and Media Contact:
Vice President, Investor Relations & Corporate Communications